31 July 2013
The Kaluga region in Central Russia, the city of Kaluga and NovaMedica, a young Russian pharma, have agreed to build a new pharmaceutical factory in the area, Rusnano reports .
The new project is part of a joint effort between Rusnano, Russia’s largest nanotech company, and Domain Associates, a leading US-based VC fund. NovaMedica is a year-old subsidiary of the Russian and American partners in the effort.
The factory is expected to manufacture innovation drugs and medical products that will be authorized for Russia-based production within the framework of Rusnano and Domain Associates’ broader joint program designed to fund pharma and biomed projects at advanced stages of research.
Under the terms of this most recent agreement, the partners will build in Kaluga’s Grabtsevo Techno-park a high-tech pharmaceutical production line to comply with the GMP standards. It is expected to be sophisticated enough for its products to be approved by the U.S.’ Food and Drug Administration (FDA).
This $85m factory is also expected to create more than a hundred new local jobs.
The production facility will break ground later this year, Rusnano said.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024